Tmunity will use the proceeds to continue funding of ongoing and planned research of product candidates to treat cancer. Credit: skeeze from Pixabay.

US-based Tmunity Therapeutics has raised a $75m Series B financing led by venture capital firm Andreessen Horowitz to propel next-generation T-cell therapies.

The financing also saw the participation of Westlake Village BioPartners, Gilead Sciences, The University of Pennsylvania, Be The Match BioTherapies and BrightEdge.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Tmunity plans to use the Series B proceeds to continue funding of ongoing and planned research, as well as clinical development of product candidates.

Additionally, the company will use the financing for the continued growth of its vertically-integrated viral vector and cell therapy product manufacturing and working capital, as well as other general purposes.

According to Tmunity, the company has raised $231m since inception.

Tmunity Therapeutics president and CEO Usman Oz Azam said: “We are fortunate to be funded by impressive investors who share our commitment to patients and our vision to dramatically change the way cancer is treated.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We see ourselves leading the innovation of the future of oncology treatment by uniting our foundational competencies in cell therapy with expertise in building new constructs, translating them and getting them into the clinic.”

Andreessen Horowitz general partner Jorge Conde will join the company’s Board of Directors as part of the Series B financing.

Conde said: “Tmunity’s founders Carl June and Bruce Levine invented CAR-T, one of the most profound breakthroughs against cancer in recent history.

“Together with Oz Azam, who with his team, brought the first CAR-T therapy to market, the company has built a pioneering platform that has produced an unrivalled therapeutic pipeline with programmes already in human clinical trials for both solid and liquid tumours.”